Predictors and Implications of Renal Injury in Large Cell Lymphoma Patients Receiving CD19 CAR T Cell Therapy

被引：1

作者：

Boardman, Alexander P. ^{[1
]}

Gutgarts, Victoria ^{[1
]}

Flynn, Jessica R. ^{[2
]}

Devlin, Sean M. ^{[2
]}

Tomas, Ana Alarcon ^{[1
]}

Fein, Joshua A. ^{[3
]}

Slingerland, John ^{[1
]}

Parascondola, Allison ^{[4
]}

Lin, Richard J. ^{[5
]}

Scordo, Michael ^{[6
]}

Batlevi, Connie Lee ^{[7
]}

Dahi, Parastoo B. ^{[5
]}

Giralt, Sergio A. ^{[8
]}

Palomba, M. Lia ^{[7
]}

Salles, Gilles ^{[9
]}

Nath, Karthik ^{[4
]}

Walji, Moneeza ^{[4
]}

De Lapuerta, Magdalena Corona ^{[10
]}

Shah, Gunjan L. ^{[8
]}

Perales, Miguel-Angel ^{[5
]}

Jaffer-Sathick, Insara ^{[11
]}

Shouval, Roni ^{[5
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, New York, NY USA

[2] Mem Sloan Kettering Canc Ctr, Dept Biostat & Epidemiol, New York, NY USA

[3] Tel Aviv Univ, Chaim Sheba Med Ctr, Hematol & BMT Div, Ramat Gan, Israel

[4] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY USA

[5] Mem Sloan Kettering Canc, Adult Bone Marrow Transplant Serv, Cellular Therapy Serv, Dept Med, New York, NY USA

[6] Mem Sloan Kettering Canc Ctr New York, Dept Med, Adult Bone Marrow Transplant Serv, New York, NY USA

[7] Mem Sloan Kettering Canc Ctr, Dept Med, Lymphoma Serv, Cellular Therapy Serv, New York, NY USA

[8] Mem Sloan Kettering Canc Ctr, Dept Med, Adult Bone Marrow Transplantat Serv, New York, NY USA

[9] Mem Sloan Kettering Canc Ctr, Lymphoma Serv, Dept Med, New York, NY USA

[10] Hosp 12 Octubre, Serv Hematol, Madrid, Spain

[11] Mem Sloan Kettering Canc Ctr, Renal Serv, New York, NY USA

来源：

BLOOD | 2022年 / 140卷

关键词：

D O I：

10.1182/blood-2022-157455

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：4671 / 4672

页数：2

共 50 条

[1] Feasibility of CD19 CAR T-cell therapy in patients with cardiac lymphoma
Kuipers, Maria T.
Spanjaart, Anne M.
Bonifazi, Francesca
diBlasi, Roberta
Zinzani, Pier L.
Thieblemont, Catherine
Baudet, Mathilde
Biemond, Bart J.
Kok, Wouter E. M.
Kersten, Marie J.
LEUKEMIA & LYMPHOMA, 2024, 65 (03) : 399 - 402
[2] Predictors and implications of renal injury after CD19 chimeric antigen receptor T-cell therapy
Boardman, Alexander P.
Gutgarts, Victoria
Flynn, Jessica R.
Devlin, Sean M.
Goldman, Adam
Tomas, Ana Alarcon
Fein, Joshua A.
Slingerland, John B.
Parascondola, Allison
Lin, Richard J.
Scordo, Michael
Dahi, Parastoo B.
Geralt, Sergio A.
Palomba, M. Lia
Salles, Gilles
Nath, Karthik
Walji, Moneeza
Corona, Magdalena
Park, Jae H.
Shah, Gunjan L.
Perales, Miguel-Angel
Jaffer-Sathick, Insara
Shouval, Roni
HAEMATOLOGICA, 2025, 110 (03) : 651 - 664
[3] Biomarkers of outcome in patients undergoing CD19 CAR-T therapy for large B cell lymphoma
Gong, Inna Y.
Tran, Daisy
Saibil, Samuel
Laister, Rob C.
Kuruvilla, John
HEMASPHERE, 2024, 8 (08):
[4] Aggressive Lymphoma after CD19 CAR T-Cell Therapy
Kobbe, Guido
Bruggemann, Monika
Baermann, Ben-Niklas
Wiegand, Laura
Trautmann, Heiko
Yousefian, Schayan
Libertini, Silvana
Menssen, Hans D.
Maier, Harald J.
Ulrich, Peter
Gao, Jingbo
Bruch, Peter-Martin
Liebers, Nora
Radujkovic, Aleksandar
Seifert, Marc
Schniederjohann, Christina
Paramasivam, Nagarajan
Fitzgerald, Donnacha
Seidel, Maximilian
Esposito, Irene
Germing, Ulrich
Cadeddu, Ron-Patrick
Nachtkamp, Kathrin
Jaeger, Paul
Ulrych, Thomas
Fischer, Johannes C.
Rox, Jutta M.
Giesel, Frederik
Koch, Raphael
Antoch, Gerald
Distler, Joerg H. W.
Meuth, Sven G.
Jacobsen, Malte
Hubschmann, Daniel
Lu, Junyan
Iaccarino, Ingram
Haas, Simon
Damm, Frederik
Dietrich, Sascha
NEW ENGLAND JOURNAL OF MEDICINE, 2024, 391 (13): : 1217 - 1226
[5] Outcome and feasibility of radiotherapy bridging in large B-cell lymphoma patients receiving CD19 CAR T in the UK
Kuhnl, A.
Roddie, C.
Kirkwood, A. A.
Chaganti, S.
Norman, J.
Lugthart, S.
Osborne, W.
Gibb, A.
Gonzalez Arias, C.
Latif, A.
Uttenthal, B.
Seymour, F.
Jones, C.
Springell, D.
Brady, J. L.
Illidge, T.
Stevens, A.
Alexander, E.
Hawley, L.
O'Rourke, N.
Bedi, C.
Prestwich, R.
Frew, J.
Burns, D.
O'Reilly, M.
Sanderson, R.
Sivabalasingham, S.
Mikhaeel, N. G.
BRITISH JOURNAL OF HAEMATOLOGY, 2024, 205 (02) : 483 - 494
[6] Clinical implications for CAR T cell persistence and functional phenotype in patients treated with CD19 CAR T cell therapy.
Bochnacka, Oliwia
Quinn, Suzanne
Dalheim, Annika
Scurti, Gina
Hossain, Nasheed
Nishimura, Michael
JOURNAL OF IMMUNOLOGY, 2024, 212 (01):
[7] GENOMIC DRIVERS OF LARGE B-CELL LYMPHOMA RESISTANCE TO CD19 CAR-T THERAPY
Jain, Michael
Ziccheddu, Bachisio
Coughlin, Caroline
Faramand, Rawan
Griswold, Anthony
Reid, Kayla
Landgren, Ola
Locke, Frederick
Maura, Francesco
Davila, Marco
Schatz, Jonathan
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A703 - A703
[8] Genomic Drivers of Large B-Cell Lymphoma Resistance to CD19 CAR-T Therapy
Jain, Michael D.
Ziccheddu, Bachisio
Coughlin, Caroline A.
Faramand, Rawan
Griswold, Anthony J.
Reid, Kayla M.
Landgren, Ola
Locke, Frederick L.
Maura, Francesco
Davila, Marco L.
Schatz, Jonathan H.
BLOOD, 2021, 138
[9] Safety of Axicabtagene Ciloleucel CD19 CAR T-Cell Therapy in Elderly Patients With Relapsed or Refractory Large B-Cell Lymphoma
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (05) : 15 - 17
[10] The Lymphoma Tumor Microenvironment Influences Toxicity after CD19 CAR T Cell Therapy
Jain, Michael D.
Faramand, Rawan
Staedtke, Verena
Bai, Renyuan
Lee, Sae Bom
Kotani, Hiroshi
Reid, Kayla
Spitler, Kristen
Chavez, Julio
Shah, Bijal
Bachmeier, Christina A.
Dam, Marian
Brandjes, Brigett
Gonzalez, Ricardo J.
Mullinax, John E.
Wang, Xuefeng
Hussaini, Mohammad
Locke, Frederick L.
Davila, Marco L.
BLOOD, 2019, 134

← 1 2 3 4 5 →